Effect of Generic Competition on Atorvastatin Prescribing and Patients’ Out-of-Pocket Spending | Zendy

Jing Luo | Zendy; John D. Seeger | Zendy; Macarius Donneyong | Zendy; Joshua J. Gagne | Zendy; Jerry Avorn | Zendy; Aaron S. Kesselheim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Generic Competition on Atorvastatin Prescribing and Patients’ Out-of-Pocket Spending

Author(s) -

Jing Luo,

John D. Seeger,

Macarius Donneyong,

Joshua J. Gagne,

Jerry Avorn,

Aaron S. Kesselheim

Publication year - 2016

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2016.3384

Subject(s) - atorvastatin , medicine , medical prescription , competition (biology) , brand names , generic drug , statin , prescription drug , pharmacy , family medicine , drug , pharmacology , marketing , business , ecology , biology

In November 2011, the cholesterol level-lowering medication atorvastatin calcium became available in the United States as a generic drug. However, only a single generic form (from a manufacturer that qualified for market exclusivity by challenging several of Pfizer's patents) and an authorized generic form (a brand-name drug sold as a generic) were available for the first 180 days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research